$CTSO

CytoSorbents (CTSO) announced it regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The company's stock closed at or above this price for 10 consecutive trading sessions. CytoSorbents is also working to meet other Nasdaq listing requirements by December 28, 2026. The company aims to drive sales, achieve cash flow breakeven, and advance regulatory approvals for its products.

Cytosorbents Corp (CTSO) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement PRINCETON, N.J., September 23, 2026 -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blo

Chan Phillip P. (Chief Executive Officer) purchased 3,774 shares of Cytosorbents Corp (CTSO) at $6.00 on 2026-09-15.

Capponi Vincent (President and COO) purchased 2,073 shares of Cytosorbents Corp (CTSO) at an average of $6.05 ($5.90–$6.07) across 2 trades on 2026-09-14.

Sobel Alan D. purchased 2,500 shares of Cytosorbents Corp (CTSO) at an average of $6.10 ($6.01–$6.12) across 3 trades on 2026-09-15.

Chan Phillip P. (Chief Executive Officer) purchased 200,000 shares of Cytosorbents Corp (CTSO) at $0.35 on 2026-09-04.

Cytosorbents Corp (CTSO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders CytoSorbents Corporation (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on August 13, 2026. At the Annual Meeting, the following matters were submitted to a vote of stockholders: 1.

Cytosorbents (CTSO) reported Q2 2026 revenue of $9.6 million, flat vs. the prior year and up 9% sequentially, with 73% gross margin. Adjusted EBITDA loss was $1.6 million, a 38% improvement. Net loss was $4.4 million. Management discussed FDA strategy for DrugSorb-ATR after a de novo denial, and progress on HemoDefend-BGA. Cash was $5.9 million.

CytoSorbents (NASDAQ: CTSO) reported Q2 2026 revenue of $9.6 million, unchanged year over year. Gross margin rose to 73%. Operating loss fell 27% to $2.6 million, and net loss was $4.4 million ($0.07/share). Adjusted net loss improved 22% to $2.8 million. Cash burn was $0.4 million. The company also discussed sales trends and FDA regulatory plans.

Cytosorbents Corp (CTSO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update Highlighting Four Independent Drivers of Shareholder Value PRINCETON, N.J., August 6, 2026 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatme